Medivir AB extends the HIV-protease inhibitor collaboration agreement with Tibotec

Medivir AB extends the HIV-protease inhibitor collaboration agreement with
Tibotec 

Medivir AB (OMX Nordic: MVIR B) announced today that their research development
and license agreement, in the field of HIV-protease inhibitors, with Tibotec
Pharmaceuticals Ltd. is extended for a further year and includes research
funding. The programme is presently in preclinical research. 

For additional information, please contact
Rein Piir, CFO & VP Investor Relations, Medivir +46 8 5468 3123 or +46 708 537
292.

For more on Medivir, please see the company website: www.medivir.se